Advanced Search

 

Study ID Status Title Patient Level Data
49653/342 Completed A Randomised study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated with Avandia Study Listed on ClinicalStudyDataRequest.com
49653/347 Completed A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled on Insulin Study Listed on ClinicalStudyDataRequest.com
49653/351 Completed A 12 month randomized, double-blind, placebo-controlled, magnetic resonance imaging study to evaulate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes Study Listed on ClinicalStudyDataRequest.com
49653/352 Completed A 16 Week Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Rosiglitazone on Myocardial Glucose Uptake in Subjects with Type 2 Diabetes Mellitus and Stable Coronary Heart Disease Study Listed on ClinicalStudyDataRequest.com
49653/369 Completed A six-month double-blind, randomised, parallel-group study to compare the effect of oral rosiglitazone (less than or equal to 4mg bd) versus oral glibenclamide therapy (less than or equal to 15mg daily) on body fat distribution when administered to subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
49653/374 Completed Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients with Type 2 Diabetes Mellitus
49653/375 Completed A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects. Study Listed on ClinicalStudyDataRequest.com
49653/376 Completed A 16-week, randomised, double-blind, placebo-controlled, single-centre study to investigate fluid retention in insulin-treated subjects with type 2 diabetes mellitus and varying degrees of autonomic neuropathy when administered rosiglitazone 4 mg bd Study Listed on ClinicalStudyDataRequest.com
49653/398 Completed A study to evaluate the pharmacokinetics of six prototype formulations of rosiglitazone 8 mg in healthy volunteers after repeat dosing.
49653/411 Completed A Study to Evaluate the Effect of Single and Repeat Doses of Rosiglitazone on the Pharmacokinetics of Methotrexate in Patients Receiving Methotrexate for Psoriasis Study Listed on ClinicalStudyDataRequest.com
49653/413 Completed A study to evaluate the effect of repeat doses of rosiglitazone on the pharmacokinetics of repeat doses of acitretin in patients receiving acitretin for psoriasis. Study Listed on ClinicalStudyDataRequest.com
49653/414 Completed An open-label, non-randomized, two period study to investigate the pharmacokinetics of rosiglitazone and glibenclamide when administered alone and concomitantly in healthy male Japanese and Caucasian subjects. Study Listed on ClinicalStudyDataRequest.com
49653/452 Completed A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS) Study Listed on ClinicalStudyDataRequest.com
49653/902 Completed An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Rosiglitazone when Co-administered with Gemfibrozil in Healthy Adult Subjects Study Listed on ClinicalStudyDataRequest.com
49653/903 Completed A randomized, open-label, two-period crossover study to demonstrate the bioequivalence of twice-daily immediate release and once-daily extended release rosiglitazone dosing over five days in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
497115/003 Completed A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy
580299/001 Completed A double-blind, placebo-controlled, randomised study of the efficacy of an HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in healthy adolescent and young adult women in North America and Brazil. Study Listed on ClinicalStudyDataRequest.com
580299/002 Completed A Phase I Study of the Safety and Immunogenicity of MEDI-517, a Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers. Study Listed on ClinicalStudyDataRequest.com
580299/003 Completed A Phase I/II Study to evaluate the safety and immunogenicity of MEDI-517, a virus-like particle vaccine against human papillomavirus (HPV) types 16 and 18, in healthy adult female volunteers who are HPV-16 or HPV-18 DNA positive Study Listed on ClinicalStudyDataRequest.com
580299/004 Completed Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/005 Completed A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
580299/007 Completed Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001 Study Listed on ClinicalStudyDataRequest.com
580299/008 Completed A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age. Study Listed on ClinicalStudyDataRequest.com
580299/011 Completed An observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years Study Listed on ClinicalStudyDataRequest.com
580299/012 Completed Immunogenicity: 3 consecutive lots of GSK Biologicals’ HPV-16/18 vaccine administered intramuscularly at 0,1,6 month schedule in healthy females aged 10–25 years and demonstrate non-inferiority of candidate HPV vaccine manufactured by modified production process Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.